Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
4.
Regul Toxicol Pharmacol ; 120: 104843, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33340644

RESUMEN

This study assesses whether currently available acute oral toxicity (AOT) in silico models, provided by the widely employed Leadscope software, are fit-for-purpose for categorization and labelling of chemicals. As part of this study, a large data set of proprietary and marketed compounds from multiple companies (pharmaceutical, plant protection products, and other chemical industries) was assembled to assess the models' performance. The absolute percentage of correct or more conservative predictions, based on a comparison of experimental and predicted GHS categories, was approximately 95%, after excluding a small percentage of inconclusive (indeterminate or out of domain) predictions. Since the frequency distribution across the experimental categories is skewed towards low toxicity chemicals, a balanced assessment was also performed. Across all compounds which could be assigned to a well-defined experimental category, the average percentage of correct or more conservative predictions was around 80%. These results indicate the potential for reliable and broad application of these models across different industrial sectors. This manuscript describes the evaluation of these models, highlights the importance of an expert review, and provides guidance on the use of AOT models to fulfill testing requirements, GHS classification/labelling, and transportation needs.


Asunto(s)
Simulación por Computador , Citotoxinas/toxicidad , Colaboración Intersectorial , Etiquetado de Productos/clasificación , Etiquetado de Productos/normas , Relación Estructura-Actividad Cuantitativa , Administración Oral , Alternativas a las Pruebas en Animales/clasificación , Alternativas a las Pruebas en Animales/métodos , Alternativas a las Pruebas en Animales/normas , Animales , Industria Química/clasificación , Industria Química/normas , Simulación por Computador/tendencias , Citotoxinas/administración & dosificación , Citotoxinas/química , Bases de Datos Factuales , Industria Farmacéutica/clasificación , Industria Farmacéutica/normas , Humanos
5.
Cancer Biol Ther ; 6(4): 494-503, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17374985

RESUMEN

High-selenium containing yeast is being evaluated in clinical trials against colon polyp recurrence. However, the molecular targets for the anticancer effects of selenium remain unclear. Previous studies by our group demonstrated that selenomethionine-induced growth arrest appears to be mediated by activation of ERK and subsequent phosphorylation of RSK and histone H3. These results suggest that selenomethionine can alter gene expression. In the present study, we have used cDNA microarrays to determine whether gene expression differences exist in HCT116 colon cancer cells treated with selenomethionine. These experiments reveal statistically significant expression changes for 50 genes. Genes we found to increase with selenomethionine treatment include KLK6, ATOX1, SGK, GJB2, DAP-1, PLAU, VIM, DPYSL2, STC2 and PXN. Conversely, genes downregulated by selenomethionine include PRKACB, LIM, DEPP, MYC, CDH5, ELF3, VSNL1, SAT and EGLN3. Further analysis of those genes using chromatin immunoprecipitation experiments showed that phosphorylated histone H3 on serine 10 bound to the GJB2 promoter (connexin 26) or the serum glucocorticoid kinase promoter is increased with selenomethionine treatment. Cells overexpressing CX26 or DAP-1 displayed a reduced number of colonies which suggests that these two genes could play a functional role in the growth inhibitory effects of selenomethionine. These data support the notion that selenomethionine-induced growth inhibition is associated with global changes in gene expression. They also demonstrate that selenomethionine can modify chromatin state to alter gene transcription. Finally, our studies provide a practical foundation for the further development of biomarkers to monitor the efficacy of selenomethionine in clinical trials.


Asunto(s)
Neoplasias del Colon/genética , Perfilación de la Expresión Génica , Expresión Génica/efectos de los fármacos , Genes Relacionados con las Neoplasias , Selenometionina/farmacología , Línea Celular Tumoral , Cromatina/efectos de los fármacos , Conexina 26 , Conexinas/genética , Histonas/efectos de los fármacos , Humanos , Proteínas Inmediatas-Precoces/genética , Análisis de Secuencia por Matrices de Oligonucleótidos , Regiones Promotoras Genéticas/efectos de los fármacos , Proteínas Serina-Treonina Quinasas/genética
6.
Cancer Lett ; 222(1): 119-24, 2005 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-15837549

RESUMEN

Human mammary carcinoma MCF-7 cell line responsiveness to the pteridines xanthopterin and isoxanthopterin was studied using the MTS assay for measurement of cell viability. The pteridines were tested at concentrations ranging from 7.8 to 500 microM singly and in 11 isoxanthopterin:xanthopterin ratios. IC50s of xanthopterin and isoxanthopterin were 109+/-13 microM (mean+/-SEM of y estimate) and 103+/-9 microM, respectively. The IC50 values for pteridine mixtures were similar although 3:1 and 4:1 isoxanthopterin:xanthopterin ratios seemed slightly more cytotoxic than other mixtures. However, ANOVA revealed no statistical differences in the cytotoxicity of mixtures.


Asunto(s)
Supervivencia Celular/efectos de los fármacos , Xantopterina/farmacología , Antineoplásicos/farmacología , Neoplasias de la Mama , Línea Celular Tumoral , Combinación de Medicamentos , Sinergismo Farmacológico , Humanos , Concentración 50 Inhibidora , Xantopterina/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...